文献速递泌尿生殖与妇科肿瘤放疗

单次大剂量HDR近距离放疗与两次或三次分割治疗局部晚期前列腺癌的比较

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.
PubMed 文献 · Radiother Oncol · 2017-06-27

一项II期研究纳入293例中高危局限期前列腺癌患者,分别接受单次19-20Gy、2次13Gy或3次10.5Gy的高剂量率近距离放疗。中位随访49-108个月,4年生化无复发生存率三组相似(94%、93%、91%,p=0.54),单次组晚期泌尿和胃肠道毒性发生率与分次组相当。

要点

  • 单次19-20Gy与2次或3次分割的4年生化控制率相似
  • 单次组晚期GU-3和GI-3发生率低,与分次组相当
  • 风险分组是唯一显著独立复发预测因素

核心结论

  • 单次19-20Gy的高剂量率近距离放疗在晚期泌尿和胃肠道毒性及生化控制方面与2次或3次分割治疗相似。

研究设计与样本

  • II期研究纳入293例中高危局限期前列腺癌患者,分别接受单次19Gy或20Gy(49例)、2次13Gy(138例)或3次10.5Gy(106例)。

主要发现

  • 中位随访分别为49、63和108个月(单次组、2次组和3次组)。
  • 4年生化无复发生存率分别为94%(单次组)、93%(2次组)和91%(3次组)(p=0.54)。
  • 风险分组是唯一显著的独立复发预测因素(p<0.0001)。
  • 4年GU-3的Kaplan-Meier估计值分别为2%(单次组和2次组)和11%(3次组),GI-3分别为0%(单次组和2次组)和1%(3次组)。
  • 未观察到GU或GI 4级事件;IPSS≥20的比例分别为11%(单次组)、9%(2次组)和16%(3次组)(p=0.9)。

关键数值与推荐

  • 单次组剂量为19Gy或20Gy,2次组为2×13Gy,3次组为3×10.5Gy。
  • 3组GU-3患病率在所有时间点均≤4%,GI-3低或不存在,导管使用率在所有组均≤6%。

临床怎么用

  • 单次19-20Gy的高剂量率近距离放疗可作为中高危局限期前列腺癌的分次治疗方案之一,其晚期毒性和生化控制与2次或3次分割相似。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer. PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS). RESULTS: Median follow-up is 49, 63 and 108months (A, B and C, respectively). At 4years biochemical relapse free survival was 94% (A), 93% (B) and 91% (C) (p=0.54). Risk-category was the only significant independent predictor of relapse (p<0.0001). Kaplan-Meier 4-year-estimates of GU-3 were 2% (A and B) and 11% (C). GI-3 was 0% (A and B) and 1% (C). No GU or GI grade-4 events were observed. IPSS≥20 was 11% (A), 9% (B) and 16% (C) (p=0.9). Prevalence of GU-3 was ≤4% in the 3 groups at all times; GI-3 was low or non-existent. Prevalence of catheter use was ≤6% in all groups. CONCLUSIONS: A single dose of 19-20Gy achieves similar rates of late morbidity and biochemical control compared to 2 and 3 fractions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hoskin P, Rojas A, Ostler P, et al. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2017. PMID: 28666552. doi:10.1016/j.radonc.2017.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。